Clinical Trials Logo

Clinical Trial Summary

In this Randomized Controlled Trial, the investigators will recruit 42 men attending the STI and HIV clinic at the Institute of Tropical Medicine, with a diagnosis of N. gonorrhoeae and randomize them 1:1 to receive either ceftriaxone or ceftriaxone/azithromycin. They will be followed-up for a test of cure visit at day 14 post-treatment where urine, oropharyngeal and anorectal samples will be taken to test for cure and monitor treatment effects on the microbiome and resistome. The primary outcome will be evaluating the difference in the abundance of resistance conferring genes in the rectal microbiome in the two arms, 14 days after the receipt of therapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05027516
Study type Interventional
Source Institute of Tropical Medicine, Belgium
Contact
Status Completed
Phase Phase 4
Start date January 17, 2022
Completion date May 9, 2022

See also
  Status Clinical Trial Phase
Completed NCT03676816 - Self Sampling for Rapid Turnaround Testing in the Emergency Department N/A
Completed NCT00213018 - Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission Phase 2
Terminated NCT03222401 - Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males Phase 2
Completed NCT00973466 - Prevalence of Sexually Transmitted Infections (STIs) in HIV-infected Patients N/A
Recruiting NCT04446611 - Clinical Study of STI Screening to Prevent Adverse Birth and New-born Outcomes N/A
Not yet recruiting NCT06216964 - Time to Clearance of Chlamydia Trachomatis and Neisseria Gonorrhoeae RNA After Treatment: a Prospective Cohort Study N/A
Completed NCT00207454 - Optimizing Strategies to Improve STD Partner Services Phase 1
Completed NCT01665690 - Washington State Community Expedited Partner Treatment (EPT) Trial Phase 4
Completed NCT00213031 - Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide Phase 2